당뇨병을 동반하지 않는 심부전 환자에서 SGLT2 Inhibitor의 심장기능에 대한 효과
Evaluation of Cardiac Function Outcomes in Non-Diabetic Heart Failure Patients Treated with SGLT2 Inhibitors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Extensive clinical studies have demonstrated that irrespective of diabetes status, sodium glucose co-transporter 2 inhibitors (SGLT2i) effectively reduce heart failure-related hospitalizations, and are advantageous in enhancing cardiac function. However, limited domestic studies have focused on the effects of SGLT2i in non-diabetic heart failure (HF) patients. Therefore, this study aims to investigate the cardiac function effects of SGLT2i in Korean HF patients without diabetes. Methods : This retrospective study analyzed electronic medical records from January 2021 to December 2022. We focused on adult HF patients without diabetes who started SGLT2i therapy at Tertiary Hospital. The evaluation of cardiac function improvement involved comparing echocardiographic parameters before the initiation of SGLT2i therapy, and at intervals ranging (3 to 12) months post-therapy. Results : This study comprised 128 patients, divided into two groups based on left ventricular ejection fraction (LVEF) and SGLT2i type. The median duration of follow-up was 189 days. Following treatment with SGLT2i, significant reductions were observed in left ventricular end-diastolic dimension (−2.7 mm; p<0.01), left ventricular end-systolic dimension (−3.3 mm; p<0.01), left ventricular mass index (−11.5 g/m2; p<0.01), and left atrium volume index (−4.5 mL/m2; p<0.01). Furthermore, significant improvement in LVEF was observed, showing an increase of 3.9% (p<0.01). The enhancement of cardiac function following SGLT2 inhibitor treatment was notably more significant in patients with LVEF ≤ 40%. Conclusion : The findings of this study demonstrate that in Korean non-diabetic HF patients, SGLT2i led to significant improvements in cardiac function, as evidenced by echocardiographic parameter alterations. Notably, these improvements were more pronounced in patients with reduced ejection fraction. Additionally, the study found no significant difference in cardiac function outcomes between empagliflozin and dapagliflozin treatments. This suggests that SGLT2i may offer a viable therapeutic option for managing HF with reduced ejection fraction in non-diabetic patients.
Abstract
Background : Extensive clinical studies have demonstrated that irrespective of diabetes status, sodium glucose co-transporter 2 inhibitors (SGLT2i) effectively reduce heart failure-related hospitalizations, and are advantageous in enhancing cardiac function. However, limited domestic studies have focused on the effects of SGLT2i in non-diabetic heart failure (HF) patients. Therefore, this study aims to investigate the cardiac function effects of SGLT2i in Korean HF patients without diabetes. Methods : This retrospective study analyzed electronic medical records from January 2021 to December 2022. We focused on adult HF patients without diabetes who started SGLT2i therapy at Tertiary Hospital. The evaluation of cardiac function improvement involved comparing echocardiographic parameters before the initiation of SGLT2i therapy, and at intervals ranging (3 to 12) months post-therapy. Results : This study comprised 128 patients, divided into two groups based on left ventricular ejection fraction (LVEF) and SGLT2i type. The median duration of follow-up was 189 days. Following treatment with SGLT2i, significant reductions were observed in left ventricular end-diastolic dimension (−2.7 mm; p<0.01), left ventricular end-systolic dimension (−3.3 mm; p<0.01), left ventricular mass index (−11.5 g/m2; p<0.01), and left atrium volume index (−4.5 mL/m2; p<0.01). Furthermore, significant improvement in LVEF was observed, showing an increase of 3.9% (p<0.01). The enhancement of cardiac function following SGLT2 inhibitor treatment was notably more significant in patients with LVEF ≤ 40%. Conclusion : The findings of this study demonstrate that in Korean non-diabetic HF patients, SGLT2i led to significant improvements in cardiac function, as evidenced by echocardiographic parameter alterations. Notably, these improvements were more pronounced in patients with reduced ejection fraction. Additionally, the study found no significant difference in cardiac function outcomes between empagliflozin and dapagliflozin treatments. This suggests that SGLT2i may offer a viable therapeutic option for managing HF with reduced ejection fraction in non-diabetic patients.
참고문헌 (34)
- "2022 KSHF Guideline for the Management of HEART FAILURE" (2022)[URL]
- "Korea heart failure fact sheet 2022"[URL]
- Zinman B, "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes", N Engl J Med, 373(22), pp.2117~2128 (2015)
- McMurray JJV, "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction", N Engl J Med, 381(21), pp.1995~2008 (2019)
- Packer M, "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure", N Engl J Med, 383(15), pp.1413~1424 (2020)
- Anker SD, "Empagliflozin in Heart Failure with a Preserved Ejection Fraction", N Engl J Med, 385(16), pp.1451~1461 (2021)
- Solomon SD, "Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction", N Engl J Med, 387(12), pp.1089~1098 (2022)
- "Jardian 10 mg (empagliflozin)"[URL]
- "Forxiga 10 mg (dapagliflozin)"[URL]
- Heidenreich PA, "2022 AHA", ACC, American Heart Association Joint Committee on Clinical Practice Guidelines, pp.Circulation, 2022[DOI]
- McDonagh TA, "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J, 42(36), pp.3599~3726 (2021)
- Lopaschuk GD, "Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2(SGLT2)Inhibitors : A State-of-the-Art Review", JACC Basic Transl Sci, 5(6), pp.632~644 (2020)
- Cohn JN, "Cardiac remodeling--concepts and clinical implications : a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling", J Am Coll Cardiol, 35(3), pp.569~582 (2000)
- Aimo A, "Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction", JACC Heart Fail, 7(9), pp.782~794 (2019)
- "Boehringer Ingelheim. US FDA approves Jardiance (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction"[URL]
- "Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients"[URL]
- Lam CSP, "Sex differences in heart failure", Eur Heart J, 40(47), pp.3859~3868 (2019)
- Murphy WG, "The sex difference in haemoglobin levels in adults-mechanisms, causes, and consequences", Blood Rev, 28(2), pp.41~47 (2014)
- Chen YC, "Clinical Relevance of the LVEDD and LVESD Trajectories in HF Patients With LVEF < 35", Front Med(Lausanne), 9, pp.846361~ (2022)
- Choi JO, "Normal Echocardiographic Measurements in a Korean Population Study : Part I. Cardiac Chamber and Great Artery Evaluation", J Cardiovasc Ultrasound, 23(3), pp.158~172 (2015)
- Santos-Gallego CG, "Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction", J Am Coll Cardiol, 77(3), pp.243~255 (2021)
- Pascual-Figal DA, "Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure : The DAPA-MODA study", Eur J Heart Fail, 25(8), pp.1352~1360 (2023)
- Scheen AJ, "Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2diabetes : Focus on SGLT2 inhibitors and EMPA-REG OUTCOME", Diabetes Res Clin Pract, 121, pp.204~214 (2016)
- Park SY, "Comparisons of Efficacy Between Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors Add-on to Metformin Therapy in Type 2Diabetes Mellitus Patients", J. Kor. Soc. Health-syst. Pharm, 37(3), pp.341~352 (2020)
- Teo YH, "Effects of Sodium", Glucose Cotransporter 2(SGLT 2)Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus : A Systematic Review and Meta-Analysis of Randomized-Controlled Trials, 2021, pp.10(5), e019463~
- Januzzi JL Jr, "Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial", J Am Coll Cardiol, 78(13), pp.1321~1332 (2021)
- Vasquez N, "Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis", Curr Heart Fail Rep, 17(3), pp.67~76 (2020)
- Januzzi JL Jr, "Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction", JAMA, 322(11), pp.1085~1095 (2019)
- Fabijanovic D, "Left Ventricular Size and Ejection Fraction : Are They Still Relevant?", Heart Fail Clin, 15(2), pp.147~158 (2019)
- Hwang IC, "Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients", Cardiovasc Diabetol, 19(1), pp.69~ (2020)
- Lim J, "Comparative cardiovascular outcomes in type 2diabetes patients taking dapagliflozin versus empagliflozin : a nationwide population-based cohort study", Cardiovasc Diabetol, 22(1), pp.188~ (2023)
- Hao Z, "Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction : A Retrospective Study", Int J Gen Med, 15, pp.5915~5918 (2022)
- Alnsasra H, "Dapagliflozin versus empagliflozin in patients with chronic kidney disease", Front Pharmacol, 14, pp.1227199~ (2023)
- Shi Z, "Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure : A Network Meta-Analysis", Front Cardiovasc Med, 9, pp.869272~ (2022)